Management of Soil-transmitted Helminthiasis and Strongyloidiasis
Information source: Universidad Nacional de Salta
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Helminthiasis; Strongyloides Stercoralis Infection
Intervention: Ivermectin + Albendazole (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Universidad Nacional de Salta Official(s) and/or principal investigator(s):
Alejandro Krolewiecki, MD, PhD, Principal Investigator, Affiliation: Universidad Nacional de Salta, Instituto de Investigación en Enfermedades Tropicales
Overall contact:
Alejandro Krolewiecki, MD, PhD, Phone: +54-11-45531369, Email: alekrol@hotmail.com
Summary
The general purpose of the project is to analyse soil-transmitted helminthiases (STH) in a
highly endemic area in northern Argentina with a multidisciplinary approach. The specific
objectives are to evaluate the local epidemiology of STH, validate a new diagnostic serology
method for S. stercoralis and evaluate the efficacy and safety of a mass drug administration
regimen with albendazole and ivermectin.
Clinical Details
Official title: Community-based Approach for the Management of Soil-transmitted Helminthiasis in General and Strongyloidiasis in Particular in a Highly Endemic Area
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Evaluation of local epidemiology of soil-transmitted helminthiases and impact of a mass drug treatment anti-helminthic strategy
Secondary outcome: Validate serology methods for diagnosis of S. stercoralis infectionAssess the tolerability and safety of the combination of ivermectin and albendazole
Eligibility
Minimum age: 1 Year.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- All persons that are living in the working area at the time of the intervention and
wish to participate in the study.
Exclusion Criteria:
1. All persons that live within the study area but do not want to participate in the
study.
2. Pregnant women or women who are likely pregnant.
3. Women during the first post-partum week if they are breastfeeding.
4. Children who weigh less than 15 kg.
5. Persons with a history of hypersensitivity or intolerance to ivermectin, albendazole
or to the components that make up those drugs.
Locations and Contacts
Alejandro Krolewiecki, MD, PhD, Phone: +54-11-45531369, Email: alekrol@hotmail.com
Instituto de Investigación en Enfermedades Tropicales, Universidad Nacional de Salta, Orán, Salta 4530, Argentina; Recruiting
Additional Information
Starting date: December 2010
Last updated: March 3, 2011
|
